Year |
Citation |
Score |
2023 |
Graham MK, Wang R, Chikarmane R, Wodu B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, ... ... Lupold SE, et al. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 37905029 DOI: 10.1101/2023.09.07.553268 |
0.427 |
|
2023 |
Lupold SE, Isaacs WB, Luo J. Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer. European Urology. PMID 37635043 DOI: 10.1016/j.eururo.2023.08.006 |
0.545 |
|
2021 |
Kurozumi A, Lupold SE. Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets? Asian Journal of Urology. 8: 407-415. PMID 34765448 DOI: 10.1016/j.ajur.2021.05.014 |
0.415 |
|
2021 |
Mishra A, Zennami K, Velarde E, Thorek DLJ, Yegnasubramanian S, DeWeese TL, Lupold SE. Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods. The Prostate. PMID 34032307 DOI: 10.1002/pros.24171 |
0.337 |
|
2020 |
Huang CT, Guo X, Bařinka C, Lupold SE, Pomper MG, Gabrielson K, Raman V, Artemov D, Hapuarachchige S. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Molecular Pharmaceutics. PMID 32803984 DOI: 10.1021/Acs.Molpharmaceut.0C00457 |
0.474 |
|
2019 |
Hapuarachchige S, Huang CT, Donnelly MC, Bařinka C, Lupold SE, Pomper MG, Artemov D. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Molecular Pharmaceutics. PMID 31840521 DOI: 10.1021/Acs.Molpharmaceut.9B00788 |
0.387 |
|
2019 |
Kurozumi A, Lupold SE. New functions assigned to a microRNA with genetic links to prostate cancer risk. Annals of Translational Medicine. 7: S193. PMID 31656772 DOI: 10.21037/Atm.2019.07.29 |
0.476 |
|
2019 |
Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, ... ... Lupold SE, et al. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. PMID 31043708 DOI: 10.1038/S41388-019-0823-5 |
0.416 |
|
2019 |
Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. Abstract 4501: Loss of miR-21 delays myc-driven prostate cancer progression in the hi-myc transgenic mouse model Cancer Research. 79: 4501-4501. DOI: 10.1158/1538-7445.Sabcs18-4501 |
0.455 |
|
2019 |
Imada EL, Sanchez DF, Matam T, Collado-Torres L, Wilks C, Dinalankara W, Stupnikov A, Langmead B, Lupold SE, Marchionni L. Abstract 908: Comprehensive analysis of alternative polyadenylation across cancer phenotypes Cancer Research. 79: 908-908. DOI: 10.1158/1538-7445.Am2019-908 |
0.377 |
|
2019 |
Zennami* K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. PD05-10 LOSS OF MIR-21 DELAYS MYC-DRIVEN PROSTATE CANCER PROGRESSION IN THE HI-MYC TRANSGENIC MOUSE MODEL Journal of Urology. 201. DOI: 10.1097/01.JU.0000555070.63543.0b |
0.346 |
|
2019 |
Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. Loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model European Urology Supplements. 18: e62-e63. DOI: 10.1016/S1569-9056(19)30047-8 |
0.391 |
|
2019 |
Mishra A, Zennami K, Velarde E, Coulter JB, Yegnasubramanian S, Lupold S, DeWeese TL. Circulating Tumor DNA Is an Accurate Measurement of Determining Radiation-Induced Therapeutic Response and Tumor Burden Monitoring in a Prostate Cancer Bone Metastases Murine Model International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1065 |
0.434 |
|
2018 |
Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry. PMID 30518666 DOI: 10.1373/Clinchem.2018.293365 |
0.592 |
|
2018 |
Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, Rafiqi FH, Kurozumi A, Hatano K, Lupold SE. PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance. Molecular Cancer Research : McR. PMID 30518628 DOI: 10.1158/1541-7786.Mcr-18-0837 |
0.502 |
|
2018 |
Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Scientific Reports. 8: 7189. PMID 29739972 DOI: 10.1038/S41598-018-25320-Z |
0.417 |
|
2018 |
Lupold SE. Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey. American Journal of Clinical and Experimental Urology. 6: 78-86. PMID 29666835 |
0.388 |
|
2018 |
Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Lupold S. MP29-07 LOSS OF MIR-21 DELAYS MYC-DRIVEN PROSTATE CANCER PROGRESSION IN THE HI-MYC TRANSGENIC MOUSE MODEL Journal of Urology. 199. DOI: 10.1016/S1569-9056(19)30047-8 |
0.509 |
|
2018 |
Lupold SE, Pienta KJ, Koul HK, Chung LW, Sun Y. Obituary for Donald S. Coffey: Remembering a pioneer in the field of prostate cancer research. (1932–2017) Asian Journal of Urology. 5: 1-2. DOI: 10.1016/J.Ajur.2017.11.006 |
0.446 |
|
2017 |
Martino T, Kudrolli TA, Kumar B, Salviano I, Mencalha A, Coelho MGP, Justo G, Costa PRR, Sabino KCC, Lupold SE. The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. The Prostate. PMID 29105806 DOI: 10.1002/Pros.23455 |
0.489 |
|
2017 |
Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold SE, Pienta KJ, Pomper MG. Low level endogenous prostate-specific membrane antigen (PSMA) expression in non-prostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025989 DOI: 10.2967/Jnumed.117.191221 |
0.515 |
|
2017 |
Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens. Bmc Cancer. 17: 32. PMID 28061773 DOI: 10.1186/S12885-016-3008-4 |
0.529 |
|
2017 |
Zennami K, Hatano K, Liao R, Rafiqi F, Choi SM, Lupold S. MP99-14 PDCD4 IS A CHECK POINT OF MIR-21 INDUCED CASTRATION RESISTANCE IN HUMAN PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3100 |
0.476 |
|
2017 |
Zennami K, Zhang Y, Zhou H, Thorek D, DeWeese T, Lupold S. MP83-12 TISSUE-SPECIFIC RADIATION SENSITIZATION OF PROSTATE CANCER BY APTAMER TARGETED SIRNA KNOCK-DOWN OF DNA REPAIR PATHWAY Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2580 |
0.47 |
|
2016 |
Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE. Identification of miR-30b-3p and miR-30d-5p as direct regulators of Androgen Receptor Signaling in Prostate Cancer by complementary functional microRNA library screening. Oncotarget. PMID 27683042 DOI: 10.18632/Oncotarget.12241 |
0.575 |
|
2016 |
Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE. Development and application of a novel model system to study 'active' and 'passive' tumor targeting. Molecular Cancer Therapeutics. PMID 27486224 DOI: 10.1158/1535-7163.Mct-16-0051 |
0.531 |
|
2016 |
Kumar B, Lupold SE. MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian Journal of Andrology. PMID 27056344 DOI: 10.4103/1008-682X.177839 |
0.449 |
|
2015 |
Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate. PMID 26499105 DOI: 10.1002/Pros.23115 |
0.464 |
|
2015 |
Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWEese TL, Lupold SE. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts. Molecular Cancer Therapeutics. PMID 26438155 DOI: 10.1158/1535-7163.Mct-15-0291-T |
0.458 |
|
2015 |
Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Research. 43: 4075-86. PMID 25845598 DOI: 10.1093/Nar/Gkv273 |
0.389 |
|
2015 |
Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 771-80. PMID 25501577 DOI: 10.1158/1078-0432.Ccr-14-0891 |
0.481 |
|
2014 |
Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. The Prostate. 74: 1655-62. PMID 25252191 DOI: 10.1002/Pros.22883 |
0.584 |
|
2014 |
Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE. A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector. The Prostate. 74: 1286-96. PMID 25065656 DOI: 10.1002/Pros.22845 |
0.305 |
|
2014 |
Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG. Evaluation of prostate-specific membrane antigen as an imaging reporter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 805-11. PMID 24700883 DOI: 10.2967/Jnumed.113.134031 |
0.385 |
|
2014 |
Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of Cellular Biochemistry. 115: 1505-15. PMID 24604720 DOI: 10.1002/Jcb.24805 |
0.486 |
|
2014 |
Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. Chemmedchem. 9: 1356-60. PMID 24591351 DOI: 10.1002/Cmdc.201300549 |
0.403 |
|
2014 |
Hatano K, Kumar B, Mears B, Chowdhury WH, Rodriguez R, Zhang Y, DeWeese TL, Lupold SE. MP24-12 FUNCTIONAL SCREENING IDENTIFIES MICRORNAS WHICH ALTER PROSTATE CANCER SENSITIVITY TO RADIATION THERAPY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.293 |
0.474 |
|
2014 |
Hedayati M, Hatano K, Kumar B, Chowdhury W, Rodriguez R, Zhang Y, DeWeese T, Lupold S. Functional Screening Identifies MicroRNAs That Alter Prostate Cancer Sensitivity to Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 90: S88-S89. DOI: 10.1016/J.Ijrobp.2014.05.482 |
0.472 |
|
2013 |
Johnson TJ, Höti N, Liu C, Chowdhury WH, Li Y, Zhang Y, Lupold SE, Deweese T, Rodriguez R. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Therapy. 20: 394-402. PMID 23764901 DOI: 10.1038/Cgt.2013.34 |
0.474 |
|
2013 |
Raval R, Ni X, Zhang Y, Zhou H, Meeker A, Lupold S, DeWeese T. Systemic Delivery of Synthesized Aptamer-siRNA Chimeras Results in Prostate-Targeted Radiosensitization International Journal of Radiation Oncology*Biology*Physics. 87: S139. DOI: 10.1016/J.Ijrobp.2013.06.358 |
0.559 |
|
2013 |
Ribas J, Lupold SE. The role of miR-21, an androgen-regulated MicroRNA, in prostate cancer Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications. 2147483647: 285-305. DOI: 10.1007/978-1-4614-6182-1_18 |
0.402 |
|
2012 |
Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. Journal of Biomedicine & Biotechnology. 2012: 180363. PMID 23093837 DOI: 10.1155/2012/180363 |
0.489 |
|
2012 |
Lupold SE, Johnson T, Chowdhury WH, Rodriguez R. A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer. Plos One. 7: e36535. PMID 22590558 DOI: 10.1371/Journal.Pone.0036535 |
0.311 |
|
2012 |
Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT, Lupold SE. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Research. 40: 6821-33. PMID 22505577 DOI: 10.1093/Nar/Gks308 |
0.34 |
|
2012 |
Wu P, Oh D, Chowdhury WH, Kudrolli TA, Liu MM, Sokoll L, Rodriguez R, Lupold SE. Abstract 2392: A novel approach for detecting viable and tissue-specific circulating tumor cells Cancer Research. 72: 2392-2392. DOI: 10.1158/1538-7445.Am2012-2392 |
0.461 |
|
2011 |
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angewandte Chemie (International Ed. in English). 50: 9167-70. PMID 21861274 DOI: 10.1002/Anie.201102872 |
0.459 |
|
2011 |
Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. The Journal of Clinical Investigation. 121: 2383-90. PMID 21555850 DOI: 10.1172/Jci45109 |
0.504 |
|
2011 |
Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE, Rodriguez R. Does valproic acid induce neuroendocrine differentiation in prostate cancer? Journal of Biomedicine & Biotechnology. 2011: 607480. PMID 20981253 DOI: 10.1155/2011/607480 |
0.461 |
|
2011 |
Ni X, Zhang Y, Ribas J, Chodhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Abstract 5387: Prostate-targeted radiosensitization via aptamer-shRNA chimeras Cancer Research. 71: 5387-5387. DOI: 10.1158/1538-7445.Am2011-5387 |
0.509 |
|
2011 |
Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. 403 GROWTH INHIBITION OF PROSTATE CANCER XENOGRAFTS UPON CHRONIC TREATMENT WITH VALPROIC ACID BY CELL CYCLE ARREST AND INHIBITION OF TUMOR VASCULATURE Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.492 |
0.427 |
|
2010 |
Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE. Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Research. 70: 9549-53. PMID 20670952 DOI: 10.1158/0008-5472.Can-10-1760 |
0.347 |
|
2010 |
Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses Cancer Gene Therapy. 17: 585-597. PMID 20448671 DOI: 10.1038/Cgt.2010.15 |
0.455 |
|
2010 |
Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. International Journal of Radiation Biology. 86: 220-9. PMID 20201650 DOI: 10.3109/09553000903419338 |
0.357 |
|
2010 |
Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (Georgetown, Tex.). 9: 923-9. PMID 20160498 DOI: 10.4161/Cc.9.5.10930 |
0.453 |
|
2010 |
Hoti NU, Mustafa S, Chowdhury W, Johnson T, Lupold SE, Rodriguez R. Abstract 1510: Improving replication kinetics by using a single shRNA p21/Waf-1 construct in backbone of prostate specific CRAd Cancer Research. 70: 1510-1510. DOI: 10.1158/1538-7445.Am10-1510 |
0.504 |
|
2010 |
Ni X, Zhang Y, Ribas J, DeWeese TL, Lupold SE. Abstract 1503: PSMA Aptamer-targeted siRNAs selectively Eehance prostate cancer radiation sensitivity Cancer Research. 70: 1503-1503. DOI: 10.1158/1538-7445.Am10-1503 |
0.535 |
|
2010 |
DeWeese T, Ni X, Zhang Y, Hedayati M, Lupold S. Substantial Increases in Prostate Cancer Tumor Control Result from a Combination of PSMA Aptamer-targeted siRNAs and Radiation International Journal of Radiation Oncology*Biology*Physics. 78: S113-S114. DOI: 10.1016/J.Ijrobp.2010.07.290 |
0.509 |
|
2009 |
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research. 69: 7165-9. PMID 19738047 DOI: 10.1158/0008-5472.Can-09-1448 |
0.455 |
|
2009 |
DeWeese T, Ni X, Zhang Y, Lupold S. PSMA Aptamer-targeted SiRNAs Selectively Enhance Prostate Cancer Radiation Sensitivity International Journal of Radiation Oncology*Biology*Physics. 75: S91-S92. DOI: 10.1016/J.Ijrobp.2009.07.225 |
0.498 |
|
2008 |
Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/Jm801055H |
0.415 |
|
2008 |
Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) Journal of Medicinal Chemistry. 51: 4504-4517. PMID 18637669 DOI: 10.1021/Jm800111U |
0.397 |
|
2007 |
Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1495-503. PMID 17565351 DOI: 10.1038/Sj.Mt.6300223 |
0.482 |
|
2006 |
Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 768-78. PMID 16990052 DOI: 10.1016/J.Ymthe.2006.07.009 |
0.367 |
|
2006 |
Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 319: 533-42. PMID 16868035 DOI: 10.1124/Jpet.106.106658 |
0.447 |
|
2005 |
Lupold SE, Rodriguez R. Adenoviral gene therapy, radiation, and prostate cancer. Reviews in Urology. 7: 193-202. PMID 16985830 |
0.374 |
|
2004 |
Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Molecular Cancer Therapeutics. 3: 597-603. PMID 15141017 |
0.343 |
|
2004 |
Lupold SE, Rodriguez R. 275. Prostate Targeting Peptides Via the Prostate Specific Membrane Antigen Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.212 |
0.456 |
|
2002 |
Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62: 4029-33. PMID 12124337 |
0.595 |
|
Show low-probability matches. |